Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis

Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis

Abstract Background The prognostic significance of TP53 concurrent mutations in patients with epidermal growth factor receptor (EGFR)- or anaplastic lymphoma kinase (ALK)- mutated advanced non–small-cell lung cancer (NSCLC) who received EGFR-tyrosine kinase inhibitors (TKIs) or ALK-TKIs based target...

Full description

Bibliographic Details
Main Authors:	Kang Qin, Helei Hou, Yu Liang, Xiaochun Zhang
Format:	Article
Language:	English
Published:	BMC 2020-04-01
Series:	BMC Cancer
Subjects:	Tumor protein 53 Non-small-cell lung cancer Epidermal growth factor receptor Anaplastic lymphoma kinase Tyrosine kinase inhibitors
Online Access:	http://link.springer.com/article/10.1186/s12885-020-06805-5

Similar Items

Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
by: Wen M, et al.
Published: (2018-11-01)

Will the clinical development of 4th-generation “double mutant active” ALK TKIs (TPX-0131 and NVL-655) change the future treatment paradigm of ALK+ NSCLC?
by: Sai-Hong Ignatius Ou, et al.
Published: (2021-11-01)

Concomitant <i>TP53</i> Mutation Confers Worse Prognosis in <i>EGFR</i>-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs
by: Matteo Canale, et al.
Published: (2020-04-01)

Tyrosine kinase inhibitors for EGFR- and ALK-mutated non-small cell lung cancer
by: Jonathan R. Thompson, et al.
Published: (2016-10-01)

Research Progress on the Combination Therapy of EGFR-TKIs and Metformin  in Acquired Resistance to EGFR-TKIs in Non-small Cell Lung Cancer
by: Jiamin WANG, et al.
Published: (2023-11-01)

The prognostic implications of EGFR mutation and ALK rearrangement for the long‐term outcomes of patients with resected lung adenocarcinomas
by: Hyungjin Kim, et al.
Published: (2019-07-01)

NPM-ALK: A Driver of Lymphoma Pathogenesis and a Therapeutic Target
by: Elissa Andraos, et al.
Published: (2021-01-01)

Research Progress of New Generation EGFR-TKIs after Third-generation
by: Yuanyuan LIU, et al.
Published: (2020-11-01)

ALK F1174S mutation impairs ALK kinase activity in EML4-ALK variant 1 and sensitizes EML4-ALK variant 3 to crizotinib
by: Jikui Guan, et al.
Published: (2024-01-01)

Influence of PD‐L1 expression on the efficacy of EGFR‐TKIs in EGFR‐mutant non‐small cell lung cancer
by: Si‐Yu Lei, et al.
Published: (2023-08-01)

Detection and Evaluation of EGFR Mutation Status in Serum of Patients with Advanced Non-small Cell Lung Cancer Treated with EGFR-TKIs
by: Ling MA, et al.
Published: (2013-06-01)

Advances in Double Mutations of EGFR and ALK Gene in Non-small Cell Lung Cancer
by: Xin WANG, et al.
Published: (2018-09-01)

Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLC
by: Hou H, et al.
Published: (2019-06-01)

Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK+ Lung Cancer Patients with Poor Survival
by: Petros Christopoulos, et al.
Published: (2019-01-01)

Remarkable Clinical Response of ALK-Rearranged/TP53-Mutant Lung Adenocarcinoma with Liver Metastasis to Atezolizumab-Bevacizumab-Carboplatin-Paclitaxel After ALK Inhibitors: A Case Report
by: Iso H, et al.
Published: (2023-06-01)

Efficacy of Chemotherapy after EGFR-TKIs Resistance in 191 Patients with Unknow EGFR Gene Mutation in Advanced Lung Adenocarcinoma
by: Ping HE, et al.
Published: (2013-10-01)

Relationship between EGFR, ALK Gene Mutation and Imaging  and Pathological Features in Invasive Lung Adenocarcinoma
by: He YANG, et al.
Published: (2022-03-01)

CT features associated with EGFR mutations and ALK positivity in patients with multiple primary lung adenocarcinomas
by: Xiaoyu Han, et al.
Published: (2020-07-01)

Effects of EGFT-TKIs on Sequential Pemetrexed  for Advanced Pulmonary Adenocarcinoma
by: Xiangying WANG, et al.
Published: (2012-05-01)

Investigating the Efficacy of EGFR-TKIs and Anti-VEGFR Combination in Advanced Non-Small Cell Lung Cancer: A Meta-Analysis
by: Prashant Sakharkar, et al.
Published: (2024-03-01)

Successful Treatment of Combined Large Cell Neuroendocrine Carcinoma Harboring an EGFR Mutation with EGFR-TKIs plus Bevacizumab: A Case Report
by: Satoshi Muto, et al.
Published: (2020-11-01)

The role of EGFR‐TKIs as adjuvant therapy in EGFR mutation‐positive early‐stage NSCLC: A meta‐analysis
by: Chutong Lin, et al.
Published: (2021-04-01)

Local Treatment Combined with EGFR-TKIs for Advanced Non-small Cell Lung Cancer with Solitary Progression during EGFR-TKI Treatment
by: Xin ZHANG, et al.
Published: (2013-10-01)

Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations
by: Fang Wang, et al.
Published: (2019-03-01)

Prognostic Analysis of EGFR-TKIs Combined with Gamma Knife in EGFR-mutant Lung Adenocarcinoma with Brain Metastasis
by: Limin CHEN, et al.
Published: (2019-05-01)

Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance
by: Wen-Shuo Wu, et al.
Published: (2014-06-01)

Emerging EGFR-Mutated Subclones in a Patient With Metastatic ALK-Rearranged Lung Adenocarcinoma Treated With ALK-Targeted Therapy: A Case Report
by: Jackson Ka Chun Leung, M.B.B.S., et al.
Published: (2023-07-01)

Efficacy and resistance of EGFR-TKIs for first-line treatment for compound EGFR mutations positive non-small cell lung cancer
by: GUAN Xuhui, et al.
Published: (2022-12-01)

A case of concomitant EGFR/ALK alteration against a mutated EGFR background in early-stage lung adenocarcinoma
by: Ki-Chang Lee, et al.
Published: (2021-03-01)

Successful salvage surgery followed by second ALK–TKI after alectinib failure in a patient with ALK-positive NSCLC
by: Hiroshi Hashimoto, et al.
Published: (2022-04-01)

MOLECULAR BIOLOGICAL CHARACTERISTICS OF ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA
by: E. V. Chernyshova, et al.
Published: (2017-01-01)

An insight into lung cancer: a comprehensive review exploring ALK TKI and mechanisms of resistance
by: Adela Patcas, et al.
Published: (2022-02-01)

The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer
by: Yue Pan, et al.
Published: (2021-10-01)

Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond
by: Niki Karachaliou, et al.
Published: (2014-09-01)

Examining the Effect of ALK and EGFR Mutations on Survival Outcomes in Surgical Lung Brain Metastasis Patients
by: Sneha Sai Mannam, et al.
Published: (2023-09-01)

Primary Application of Radiofrequency Ablation after Locally Progression of EGFR-TKIs in Non-small Cell Lung Cancer
by: Baodong LIU, et al.
Published: (2016-12-01)

Advances in Long Non-coding RNAs on Resistant to EGFR-TKIs  in Non-small Cell Lung Cancer
by: Shubin LI, et al.
Published: (2018-02-01)

Targeting ALK in Cancer: Therapeutic Potential of Proapoptotic Peptides
by: Arthur Aubry, et al.
Published: (2019-02-01)

Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC
by: Qian Zhu, et al.
Published: (2017-06-01)

Clinical and computed tomography characteristics of non‐small cell lung cancer with ALK gene rearrangement: Comparison with EGFR mutation and ALK/EGFR‐negative lung cancer
by: Mio Mori, et al.
Published: (2019-04-01)